CN1682730A - Cepharanthine slow releasing preparation - Google Patents
Cepharanthine slow releasing preparation Download PDFInfo
- Publication number
- CN1682730A CN1682730A CN 200510008585 CN200510008585A CN1682730A CN 1682730 A CN1682730 A CN 1682730A CN 200510008585 CN200510008585 CN 200510008585 CN 200510008585 A CN200510008585 A CN 200510008585A CN 1682730 A CN1682730 A CN 1682730A
- Authority
- CN
- China
- Prior art keywords
- cepharanthine
- slow releasing
- cellulose
- releasing preparation
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of slow releasing cepharanthine preparation. The preparation includes cepharanthine and pharmaceutically acceptable release delaying supplementary material in the weight ratio of 2-8 to 1-7. The slow releasing preparation includes skeleton type slow releasing preparation, film controlled slow releasing preparation, penetrating pump type slow releasing preparation and slow releasing preparation prepared with microcapsule, microballoon or pill. The slow releasing cepharanthine preparation has prolonged medicine action time, reduced taking times, reduced side effect of medicine and raised medicine compliance, and is safe, effective and reliable.
Description
Technical field
The present invention relates to a kind of pharmaceutical preparation, relate in particular to a kind of cepharanthine preparation.
Background technology
(Cepharanthine, Ceph) alkaloid for extracting from Radix Stephaniae Japonicae (Stephiania japonica (Thunb.) Miers) is the ecru powder, molecular formula C to cepharanthine
37H
38N
2O
6Molecular weight 606.686, generation, antitumor, analgesia, the film with the leukopenia that alleviates anticarcinogen and cause, antiinflammatory, anti-hemolysis, enhance immunity, promotion radiation exposure mouse antibodies is stable, anticoagulant, inhibition di-phosphate ester ester activity, treatment pneumosilicosis and reduce the rat abdominal cavity leukocyte and discharge effects such as arachidonic acid and leukotriene B4.
At present domesticly developed and be applied to the clinical stephania sinica Diels tablets that is, every contains cepharanthine 20mg, and dose is each 1, every day 3 times, 1～2 month per course of treatment.Every day, oral number of times was more, and the course of treatment is long, and patient takes comparatively trouble, was prone to miss with take medicine night longly and can not keep the therapeutic effect that effective blood drug level and performance continue blanking time, the blind area in the treatment occurred.
Therefore, if develop a kind of new, convenient, effectively, long drug delivery system of action period, make it in long time range, lasting, the stable medicine that discharges quantitatively, the patient is only taken once every day, then can avoid the generation of above-mentioned unfavorable factor, and can be to the effect of curing, protecting, patient's generation is very favourable.
Summary of the invention
The object of the present invention is to provide a kind of Cepharanthine slow releasing preparation.Described Cepharanthine slow releasing preparation prolongs action time, reduces medicining times, reduces side effects of pharmaceutical drugs and improves patient's medication compliance with different release mechanism.
According to purpose of the present invention, the invention provides a kind of Cepharanthine slow releasing preparation, said preparation comprises
Cepharanthine; With
The adjuvant of pharmaceutically acceptable slow releasing function;
Both weight ratios are 2～8: 1～7.
Preferably, this slow releasing preparation comprises following composition by weight percentage:
Cepharanthine 20～80%;
Play the adjuvant 10～70% of slow releasing function;
Other adjuvant 0～70%;
Described other adjuvant is selected from plasticizer, lubricant, binding agent, solvent and excipient etc.
Wherein, plasticizer can adopt glycerol, Oleum Ricini, Polyethylene Glycol etc.;
Binding agent can adopt polyvinylpyrrolidone, sodium carboxymethyl cellulose, methylcellulose, ethyl cellulose, starch slurry etc.;
Lubricant can adopt magnesium stearate, Pulvis Talci, liquid paraffin, colloidal silica;
Solvent can adopt ethanol, water, acetone, methanol, chloroform etc.;
Excipient can adopt dextrin, starch, lactose, microcrystalline Cellulose etc.
Described Cepharanthine slow releasing preparation comprises skeleton type sustained release preparation, film controlling type slow releasing preparation, osmotic pump type slow releasing preparation and makes the slow releasing preparation that microcapsule, microsphere, piller are made again earlier.
The adjuvant of described slow releasing function is framework material and/or coating material, that is, two kinds of materials can be used separately or use in conjunction.
Described framework material is selected from cellulose derivative class, crylic acid resin, polyvinyl class and other auxiliary material.
Wherein, described cellulose derivative class is to be selected from one or more of ethyl cellulose, methylcellulose, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose;
Described crylic acid resin is acroleic acid resin II and/or acroleic acid resin III;
Described polyvinyl class is to be selected from one or more of polyvinylpyrrolidone, polyvinyl alcohol, polystyrene, polrvinyl chloride;
Described other auxiliary material is for being selected from one or more of octadecanol alkane, chitin, stearic acid, Polyethylene Glycol, gelatin, mannitol, sorbitol.
Described coating material is selected from esters, acrylic homopolymer and copolymer and the natural pharmaceutical polymers of cellulose esters, cellulose ethers, cellulose ether.
Wherein, described cellulose esters is cellulose acetate and/or cellulose acetate butyrate;
Described cellulose ethers is a hydroxypropyl emthylcellulose;
The esters of described cellulose ether is a hydroxypropyl methyl cellulose phthalate;
Described acrylic homopolymer and copolymer are to be selected from one or more of propenoic acid resin series, for example, acrylic resin I number, acrylic resin II number, acrylic resin III number etc.
Described natural pharmaceutical polymers is chitin and/or chitosan.
The dosage form of Cepharanthine slow releasing preparation of the present invention is mainly tablet, also can be pill, granule etc.
The cepharanthine that can comprise 40mg～400mg in the unit dosage forms of described Cepharanthine slow releasing preparation, every day, administration number of times was reduced to once by three times of ordinary preparation.In a specific embodiment of the present invention, comprise the cepharanthine of 60mg in the unit dosage forms of Cepharanthine slow releasing preparation.
Cepharanthine slow releasing preparation of the present invention can adopt this area conventional method preparation.
For example: cepharanthine is mixed with framework material, add binding agent and granulate, direct compression behind the adding lubricant.
And for example: cepharanthine is mixed with framework material or cepharanthine mixes with the excipient adjuvant, add binding agent and make medicated core, granule, pill, tablet etc., carry out coating again.
Release in vitro degree result of the test shows that Cepharanthine slow releasing sheet provided by the invention progressively discharged medicine in 12 hours, keeps the required blood drug level of treatment, thereby compares with ordinary tablet, can reach to reduce and take number of times, and effect is lasting, the purpose of taking convenience.
In order to understand essence of the present invention better,, describe in detail but do not limit the present invention below by description to better embodiment of the present invention.
The specific embodiment
The used test material of the present invention is commercially available purchase product if no special instructions.
The preparation of Cepharanthine slow releasing preparation
[embodiment 1]
The I prescription
Cepharanthine 100mg
Hydroxypropyl emthylcellulose 50mg
Lactose 20mg
Magnesium stearate 10mg
Microcrystalline Cellulose 30mg
The II preparation method
Cepharanthine was mixed with microcrystalline Cellulose 10 minutes, add hydroxypropyl emthylcellulose (HPMC), lactose mixing, be dissolved in and do the moistening soft material of making in the ethanol, granulate, drying, granulate adds the magnesium stearate mixing, and tabletting promptly gets the Cepharanthine slow releasing sheet.
[embodiment 2]
The I prescription
Cepharanthine 60mg
Hydroxypropyl emthylcellulose 12mg
Dextrin 4mg
Magnesium stearate 5mg
The II preparation method
With cepharanthine and hydroxypropyl emthylcellulose, dextrin mixing, the system soft material, 20 mesh sieves are granulated, drying, 18 order granulate add the magnesium stearate mixing, and tabletting promptly gets the Cepharanthine slow releasing sheet.
[embodiment 3]
The I prescription
Cepharanthine 200mg
Stearic acid 15mg
Ethyl cellulose 50mg
Magnesium stearate 10mg
The II preparation method
With cepharanthine and stearic acid mixing, add 10% ethyl cellulose ethanol liquid granulation, drying adds the magnesium stearate mixing, and granulate, tabletting promptly get the Cepharanthine slow releasing sheet.
[embodiment 4]
The I prescription
Label
Cepharanthine 400mg
Lactose 40mg
Ethyl cellulose 10mg
Magnesium stearate 20mg
Coating solution
Cellulose acetate 10g
PEG400 15ml
Acetone 100ml
The II preparation method
With cepharanthine and lactose mix homogeneously, add ethyl cellulose ethanol liquid system soft material, cross 16 mesh sieve system wet granulars, drying is crossed 14 mesh sieves and is granulated, and carries out tabletting, coating, laser boring, i.e. Cepharanthine slow releasing sheet behind the adding magnesium stearate mixing.
[embodiment 5]
The I prescription
Label
Cepharanthine 100mg
Mannitol 10mg
Magnesium stearate 1mg
Coating solution
Cepharanthine 20mg
Cellulose acetate 30mg
Acetone adds to 25ml
The II preparation method
With cepharanthine and mannitol mix homogeneously, add water system granule, drying, granulate carries out tabletting behind the adding magnesium stearate mixing, and with the aqueous acetone solution spray coating that contains cepharanthine, cellulose acetate, drying, laser boring promptly gets the Cepharanthine slow releasing sheet.
[embodiment 6]
The I prescription
Label
Cepharanthine 200mg
Ethyl cellulose 55mg
Magnesium stearate 3mg
Coating solution
Two cellulose acetate 3g
PEG400 2.5ml
Diethyl phthalate 2.5ml
Acetone adds 25ml
The II preparation method
Add binding agent after getting the abundant mixing of principal agent and adjuvant, the system soft material is crossed 20 order nylon sieve series wet granulars, drying, and the granulate that sieves, tabletting, coating are the Cepharanthine slow releasing sheet.
[embodiment 7]
The I prescription
The ball core
Cepharanthine 100mg
Starch 40mg
Dextrin 45mg
Coating solution
Acrylic resin II 1.5g
PEG400 3ml
Diethyl phthalate 0.01g
Pulvis Talci is an amount of
Ethanol adds to 25ml
The II preparation method
With the abundant mixing of starch, dextrin of cepharanthine and proper proportion, in coating pan, make the micropill ball heart with certain density ethanol, take out drying.Get the dry ball heart of making, weigh after removing fine powder, put coating in the coating pan, promptly get the cepharanthine controlled release micro pill, can further be processed into other dosage form.
The release in vitro degree research of Cepharanthine slow releasing preparation
[embodiment 8]
Get Cepharanthine slow releasing sheet A, B, C (respectively successively according to embodiment 1,2,6 preparations), cepharanthine ordinary tablet (every 20mg, Guiyang pharmaceutical factory of Golden Bridge) each six, 900ml 0.1mol/L HCl solution is made solvent, 37 ℃ of temperature, rotating speed 100r/min, respectively at 1,2,4,6,8,10,12 hour timing spot sampling 5ml (replenishing the same medium of 5ml simultaneously), 0.45 μ m filtering with microporous membrane, high-efficient liquid phase technique is measured the cumulative release amount, calculates relative cumulative release percentage rate.In this test, it is all better to discharge homogeneity and repeatability.The average accumulated medicine realeasing rate comparative result of Cepharanthine slow releasing sheet and cepharanthine ordinary tablet is as shown in table 1.
Result of the test shows that ordinary tablet surpasses 80% in 1 hourly average cumulative release rate, and after this release quantitative changeization is little, and the sustained-release tablets release effect is obvious, 12 hours release curve Higuchi equation, and 12 hourly average cumulative release rates can reach more than 90%.Cepharanthine slow releasing sheet of the present invention progressively discharged medicine in 12 hours, keep the required blood drug level of treatment, took number of times thereby reach to reduce, and effect is lasting, the purpose of taking convenience.
The average accumulated release percentage comparisons (n=6) of table 1 Cepharanthine slow releasing sheet and cepharanthine ordinary tablet
| Time (hour) | ????1 | ????2 | ????4 | ????6 | ????8 | ????10 | ????12 |
| Ordinary tablet (%) | ??82.37 | ??83.17 | ??84.14 | ??84.16 | ??84.20 | ??84.22 | ??84.25 |
| Slow releasing tablet A (%) | ??18.21 | ??26.89 | ??48.79 | ??56.98 | ??84.67 | ??88.75 | ??91.20 |
| Slow releasing tablet B (%) | ??20.30 | ??31.51 | ??56.72 | ??63.42 | ??84.28 | ??90.45 | ??92.83 |
| Slow releasing tablet C (%) | ??22.56 | ??32.42 | ??61.23 | ??75.54 | ??80.25 | ??91.23 | ??93.41 |
More than the description of better embodiment of the present invention is not limited the present invention, those skilled in the art can make various changes or distortion according to the present invention, only otherwise break away from spirit of the present invention, all should belong to the scope of claims of the present invention.
Claims (7)
1, a kind of Cepharanthine slow releasing preparation is characterized in that it comprises
Cepharanthine; With
The adjuvant of pharmaceutically acceptable slow releasing function;
Both weight ratios are 2～8: 1～7.
2, Cepharanthine slow releasing preparation according to claim 1 is characterized in that it comprises following component by weight percentage:
Cepharanthine 20～80%;
Play the adjuvant 10～70% of slow releasing function;
Other adjuvant 0～70%;
Described other adjuvant is selected from plasticizer, lubricant, binding agent, solvent and excipient.
3, Cepharanthine slow releasing preparation according to claim 2, the adjuvant that it is characterized in that described slow releasing function is framework material and/or coating material.
4, Cepharanthine slow releasing preparation according to claim 3 is characterized in that
Described framework material is selected from cellulose derivative class, crylic acid resin, polyvinyl class and other adjuvant;
Wherein, described cellulose derivative class is to be selected from one or more of ethyl cellulose, methylcellulose, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose;
Described crylic acid resin is acroleic acid resin II number and/or acroleic acid resin III number;
Described polyvinyl class is to be selected from one or more of polyvinylpyrrolidone, polyvinyl alcohol, polystyrene, polrvinyl chloride;
Described other adjuvant is to be selected from one or more of octadecanol alkane, chitin, stearic acid, Polyethylene Glycol, gelatin, mannitol, sorbitol;
Described coating material is selected from esters, acrylic homopolymer and copolymer and the natural pharmaceutical polymers of cellulose esters, cellulose ethers, cellulose ether;
Wherein, described cellulose esters is cellulose acetate and/or cellulose acetate butyrate;
Described cellulose ethers is a hydroxypropyl emthylcellulose;
The esters of described cellulose ether is a hydroxypropyl methyl cellulose phthalate;
Described acrylic homopolymer and copolymer are one or more of acrylic resin I number, acrylic resin II number, acrylic resin III number;
Described natural pharmaceutical polymers is chitin and/or chitosan.
5,, it is characterized in that comprising in the unit dosage forms of described Cepharanthine slow releasing preparation the cepharanthine of 40mg～400mg according to the described Cepharanthine slow releasing preparation of one of claim 1～4.
6, Cepharanthine slow releasing preparation according to claim 5 is characterized in that comprising in its unit dosage forms following component:
Cepharanthine 60mg
Hydroxypropyl emthylcellulose 12mg
Dextrin 4mg
Magnesium stearate 5mg
7, the preparation method of the described Cepharanthine slow releasing preparation of claim 6 is characterized in that cepharanthine and hydroxypropyl emthylcellulose, dextrin mixing, the system soft material, and 20 mesh sieves are granulated, drying, 18 order granulate add the magnesium stearate mixing, tabletting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100085852A CN1332668C (en) | 2005-02-23 | 2005-02-23 | Cepharanthine slow releasing preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100085852A CN1332668C (en) | 2005-02-23 | 2005-02-23 | Cepharanthine slow releasing preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1682730A true CN1682730A (en) | 2005-10-19 |
| CN1332668C CN1332668C (en) | 2007-08-22 |
Family
ID=35262350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100085852A Active CN1332668C (en) | 2005-02-23 | 2005-02-23 | Cepharanthine slow releasing preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1332668C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106508963A (en) * | 2016-09-28 | 2017-03-22 | 广州凯耀资产管理有限公司 | Slow release agent and preparation method thereof |
| CN111228330A (en) * | 2020-03-13 | 2020-06-05 | 广州暨南生物医药研究开发基地有限公司 | Stephanine-containing anti-inflammatory pharmaceutical composition and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1234361C (en) * | 2003-10-23 | 2006-01-04 | 成都一平医药科技发展有限公司 | Method for preparing medicine of levo-stephandinine |
-
2005
- 2005-02-23 CN CNB2005100085852A patent/CN1332668C/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106508963A (en) * | 2016-09-28 | 2017-03-22 | 广州凯耀资产管理有限公司 | Slow release agent and preparation method thereof |
| CN111228330A (en) * | 2020-03-13 | 2020-06-05 | 广州暨南生物医药研究开发基地有限公司 | Stephanine-containing anti-inflammatory pharmaceutical composition and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1332668C (en) | 2007-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1182363A (en) | Controlled release formulation for water soluble drugs in which passageway is formed in situ | |
| CN1921837A (en) | Method of preparing low-crystallinity oltipraz or amorphous oltipraz | |
| CN101073563A (en) | Chiral composition containing dextrothyroxine buprofenli and levomethadyl cysteliqin and its double slow-releasing tablet | |
| CN1245398C (en) | Extraction technology of baicalein, medicinal composition and preparation technology of medicine | |
| CN1225464C (en) | Extraction technology of Hanbaicalein, medicinal composition and preparation technology of medicine | |
| CN1883480A (en) | A pharmaceutical composition containing rupatatine | |
| CN1682730A (en) | Cepharanthine slow releasing preparation | |
| CN101032462A (en) | Mexiletine Hydrochloride slow release reagent and preparing method thereof | |
| CN1965817A (en) | Sustained release tablet of glibenclamide and preparation process thereof | |
| CN1270712C (en) | Felodipine controlled-release preparation | |
| CN1215845C (en) | Sustained releasing minipills of diltiazem hydrochloride and its preparation | |
| CN1543943A (en) | Oral silybin sustained release agent and preparation thereof | |
| CN1853634A (en) | Composition comprising itraconazole for oral administration | |
| CN1303990C (en) | Sodium ferulate oral disintegrating tablet and its preparation process | |
| CN1895250A (en) | Gliquilone slow-releasing preparation | |
| CN1297263C (en) | Calcium gluconate oral disintegrating tablet and its preparation process | |
| CN1861056A (en) | Slow-releasing prepn. contg. gastrodin | |
| CN1234361C (en) | Method for preparing medicine of levo-stephandinine | |
| CN1486695A (en) | Delayed releasing Acipimox prepn | |
| CN1296045C (en) | Oral disintegration tablet of dihydroergotoxine and its derivatives and its preparing process | |
| CN1298318C (en) | Sodium ferulic acid osmosis pump controlled release formulation and its preparation method | |
| CN1589782A (en) | Dimethyl biguanidine hydrochloride slow release particle and its preparation method | |
| CN1165311C (en) | Slow-releasing composition of estrogen medicine and its preparing process | |
| CN1634096A (en) | Notoginseng total saponin orally disintegrating tablet | |
| CN1273115C (en) | Quick acting and heart resurrecting oral disintegrating tablet and its preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |